10x Genomics, Inc.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
TXG$62.90-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(27,292) | $(133,599) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Stock-based compensation expense | 83,899 | 108,209 |
| Depreciation and amortization | 26,134 | 27,129 |
| Amortization of right-of-use assets | 5,582 | 6,015 |
| Fair value adjustments on contingent consideration | 1,135 | — |
| Asset and lease impairment charges | 814 | 2,454 |
| Realized loss on marketable securities | — | 3 |
| Other | (1,360) | 571 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 44,546 | 31,321 |
| Other receivables | (52,208) | — |
| Inventory | 22,371 | (19,396) |
| Prepaid expenses and other current assets | 642 | 696 |
| Other noncurrent assets | 2,290 | (1,850) |
| Accounts payable | 3,292 | 10,044 |
| Accrued compensation and other related benefits | 2,284 | (75) |
| Deferred revenue | (648) | 8,142 |
| Accrued expenses and other current liabilities | (9,939) | (17,135) |
| Operating lease liability | (7,590) | (9,763) |
| Other noncurrent liabilities | 1,321 | 646 |
| Net cash provided by operating activities | 95,273 | 13,412 |
| Investing activities: | ||
| Purchases of intangible assets | — | (1,000) |
| Asset acquisition, net | (8,616) | — |
| Purchases of property and equipment | (4,158) | (9,677) |
| Purchases of marketable securities | (98,859) | — |
| Proceeds from sales of marketable securities | — | 3,856 |
| Proceeds from maturities of marketable securities | 100,000 | 25,782 |
| Net cash provided by (used in) investing activities | (11,633) | 18,961 |
| Financing activities: | ||
| Issuance of common stock from exercise of stock options and employee stock purchase plan purchases | 4,561 | 6,397 |
| Net cash provided by financing activities | 4,561 | 6,397 |
| Effect of exchange rates changes on cash, cash equivalents, and restricted cash | 441 | 105 |
| Net increase in cash, cash equivalents, and restricted cash | 88,642 | 38,875 |
| Cash, cash equivalents, and restricted cash at beginning of period | 344,067 | 359,284 |
| Cash, cash equivalents, and restricted cash at end of period | $432,709 | $398,159 |
| Supplemental disclosures of cash flow information: | ||
| Cash paid for taxes | $1,935 | $4,863 |
| Noncash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | $135 | $954 |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $11,362 | $— |
| Common stock issued for acquisition of assets | $13,541 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.